Additional Value of New Molecular Imaging Tracers in the Detection of Recurrent/Residual Disease in Patients with Neuroendocrine Tumors Abstract #651

Introduction: Recent studies have proposed new molecular imaging tracers, such as 18F-DOPA and 68Ga-DOTANOC, for the detection of recurrent/residual neuroendocrine tumors (NET) in case of negative conventional imaging modalities.
Aim(s): To evaluate sensitivity of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in the detection of residual/recurrent NET.
Materials and methods: Fifteen patients with NET were enrolled. All had biochemical evidence of recurrent/residual disease, not evident at conventional imaging techniques. Six patients had medullary thyroid carcinoma (MTC) with post-surgical persistence of increased calcitonin, two had a suspicion of pheocromocytoma, five had SDHB and SDHD mutation gene underlying multiple/malignant polyglandular (PGL) syndrome and two had MEN-1. All patients underwent 18F-DOPA (13 cases) or 68Ga-DOTANOC PET/CT (two cases).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Andrea Lania

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Öberg K, Califano A, Strosberg J, Ma S, ...
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1820 A Nuclear Combination in Heterogeneous Metastatic Neuroendocrine Tumors
Introduction: Therapy with 177Lu-DOTATATE provides an objective response in neuroendocrine tumors (NET).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: MD Vanessa Sousa
Keywords: PRRT, 68Ga-DOTANOC
#1883 Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression
Introduction: Bronchopulmonary NETs (BPNETs) exhibit indolent to aggressive behavior. Imaging, histology and biochemistry are limited in accurately defining malignancy or progression. A blood based NET multigene test is effective in diagnosing GEP-NET progression and therapy response.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Professor Mark Kidd
Keywords: NET